Browsing by Author "Erol, Cihan"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
Publication Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort(Wiley, 2019-06-01) İdilman, Ramazan; Demir, Mehmet; Aladağ, Murat; Erol, Cihan; Çavuş, Bilger; İliaz, Raim; Köklü, Hayrettin; Çakaloğlu, Yılmaz; Şahin, Memduh; Ersöz, Galip; Köksal, İftihar; Karasu, Zeki; Özgenel, Meriç; Turan, İlker; Gündüz, Feyza; Ataseven, Hüseyin; Akdoğan, Meral; Kıyıcı, Murat; Köksal, Aydın Şeref; Akhan, Sila; Günsar, Fülya; Tabak, Fehmi; Kaymakoglu, Sabahattin; Akarca, Ulus S.; Akarsu, Mesut; Alkim, Hüseyin; Araz, Filiz; Ateş, Fehmi; Aygen, Bilgehan; Balık, İsmail; Barut, Hüseyin S.; Baysal, Birol; Bolat, Aylin; Çelik, İlhami; Coşgun, Süleyman; Ensaroglu, Fatih; Gökcan, Hale; Gürel, Selim; Gürsoy, Şebnem; İnkaya, Ahmet Çağan; Kamilli, Cemil; Kav, Taylan; Kuruüzüm, Ziya; Önder, Fatih O.; Örmeci, Necati; Özbakır, Ömer; Özenirler, Seren; Özer, Birol; Özkan, Hasan; Poturoğlu, Şule; Senates, Ebubekir; Şimşek, Halis; Toka, Bilal; Ünal, Hakan; Yaras, Serkan; Yıldırım, Abdullah E.; Yıldırım, Beytullah; Yılmaz, Bülent; Yılmaz, Hasan; Yozgat, Ahmet; Yurdaydın, Cihan; Early Access Program EAP Study Grp; KIYICI, MURAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı; 0000-0002-3208-6211; AAI-4213-2021The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P<0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P=0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC.Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements in liver function and reduces the risk of developing a new occurrence of hepatocellular carcinoma.Item Recurrence and occurrence of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment for chronic hepatitis C in patients with advanced liver disease: Turkish multi-center early access program(Elsevier, 2018-04) İdilman, Ramazan; Demir, Mehmet; Aladağ, Murat; Kaymakoğlu, Sabahattin; Erol, Cihan; Çavuş, Bilger; İliaz, Raim; Akarca, Ulus S.; Köklü, Seyfettin; Çakaloğlu, Yılmaz; Şahin, M.; Köksal, I.; Özgenel, Meriç; Toka, Bilal; Karasu, Zeki; Ersöz, Galip; Akdoğan, Meral; Kıyıcı, Murat; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; AAI-4213-2021Publication Trastuzumab ± capecitabine maintenance after the first-line treatment of HER2-positive advanced gastric cancer: Retrospective observational real-life data of Turkish oncology group(Springer, 2021-01-24) Gürbüz, Mustafa; Akkuş, Erman; Sakin, Abdullah; Urvay, Semiha; Demiray, Atike Gökçen; Şahin, Süleyman; Sakalar, Teoman; Erol, Cihan; Şendur, Mehmet Ali Nahit; Şahin, Ahmet Bilgehan; Çubukcu, Erdem; Guven, Deniz Can; Kılıçkap, Saadettin; Ergün, Yakup; Uncu, Doğan; Turhal, Nazim Serdar; Uskent, Necdet; Çınkır, Havva Yeşil; Demir, Atakan; Acar, Ramazan; Karadurmuş, Nuri; Türker, Sema; Altınbaş, Mustafa; Karaoğlan, Mert; Şenler, Filiz Çay; ŞAHİN, AHMET BİLGEHAN; ÇUBUKÇU, ERDEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-7846-0870 ; 0000-0002-0070-0889; AAM-4927-2020 ; JGT-4101-2023Purpose In the ToGA trial for HER2-positive advanced gastric cancer, cisplatin plus fluoropyrimidine was given for 6 cycles; trastuzumab was given until disease progression. However, there is a lack of real-life data about trastuzumab maintenance after 6 cycle chemotherapy. This study aims to present real-life data of trastuzumab +/- capecitabine maintenance after 6 cycles of platinum, fluoropyrimidine, and trastuzumab in non-progressive patients. Methods This is a retrospective multicenter study of the Turkish Oncology Group. A total of 35 HER2-positive, inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma patients being non-progressive at the end of 6 cycle chemotherapy and being given trastuzumab +/- capecitabine as maintenance treatment were included from sixteen oncology centers. Baseline characteristics, objective tumor responses, progression free and overall survival data, and toxicities were determined. Results About 68% of the patients were given CF, and 32% were given FOLFOX with trastuzumab as the first-line treatment. The best response in 6 cycle chemotherapy was complete 8 (22%), partial 24 (68%), and stable disease 3 (8%). All patients had trastuzumab maintenance (median cycle 13; range 7-51), and 49% of the patients had capecitabine with trastuzumab (median capecitabine cycle 6; range 2-30). The median PFS of the patients was 12.0 months (95% CI 10.3-13.7), and median OS was 17.4 months (95% CI 15.2-19.5). There were 2 patients with grade 1 cardiotoxicity. Conclusion Trastuzumab maintenance +/- capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer.